Anti-CaSR Antibodies and Hyperparathyroidism
Yes, anti-calcium-sensing receptor (anti-CaSR) antibodies are involved in rare autoimmune forms of hyperparathyroidism, though they represent an uncommon cause that should be considered in the differential diagnosis of PTH-dependent hypercalcemia.
Clinical Context and Mechanism
Anti-CaSR antibodies can cause hyperparathyroidism through two distinct mechanisms:
- Blocking antibodies: These inactivate the CaSR, mimicking familial hypocalciuric hypercalcemia (FHH), leading to what is now termed acquired hypocalciuric hypercalcemia (AHH) 1
- Biased antibodies: These paradoxically enhance Gq signaling while suppressing Gi activity, creating a unique pattern of CaSR dysregulation 2
Prevalence and Recognition
The autoimmune form is genuinely rare. In a cohort study of 75 patients with primary hyperparathyroidism, only 6.7% (5 patients) demonstrated CaSR autoantibodies 3. The most recent guidelines (2025) specifically acknowledge that "rare autoimmune forms involving anti-CaSR receptor antibodies have also been described" in the context of differential diagnosis 1.
Key Diagnostic Features to Distinguish AHH from Primary Hyperparathyroidism
When you suspect anti-CaSR antibody-mediated disease (AHH), look for these distinguishing characteristics 2:
- Hypermagnesemia (most important diagnostic clue)
- Fluctuating serum calcium levels (not the stable hypercalcemia typical of PHPT)
- Relatively lower PTH levels compared to the degree of hypercalcemia
- Absence of nephrogenic diabetes insipidus (preserved medullary hyperosmolarity)
- Less frequent acute kidney injury compared to PHPT
Clinical Pitfalls
A critical caveat: The presence of CaSR autoantibodies does not necessarily establish causation. In the study that detected these antibodies, there was no significant difference in PTH reduction after surgery between antibody-positive and antibody-negative patients, and no increased lymphocytic infiltration in parathyroid tissue of antibody-positive patients 3. This suggests that in some cases, the antibodies may be an epiphenomenon rather than the primary pathogenic mechanism.
Practical Management Approach
For mild hypercalcemia with features suggesting AHH rather than typical PHPT:
- A wait-and-see approach is reasonable given the fluctuating nature of calcium levels
- Monitor for the diagnostic features listed above, particularly magnesium levels
- Reserve immediate intervention for hypercalcemic crises
For severe hypercalcemia:
- Immediate diagnostic workup and therapeutic intervention required regardless of etiology
- Standard hypercalcemia management protocols apply
When to Consider Testing
Consider anti-CaSR antibodies in patients with:
- PTH-dependent hypercalcemia with hypermagnesemia
- Fluctuating calcium levels inconsistent with typical PHPT
- Hypocalciuric hypercalcemia without identifiable CASR, GNA11, or AP2S1 mutations
- Clinical features mimicking FHH but without family history or genetic mutations
The pathophysiological role of these autoantibodies continues to require further elucidation, but their existence as a rare cause of hyperparathyroidism is now established in current guidelines 1.